Treatment of Autism Spectrum Disorder in Children and Adolescents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Autism spectrum disorder is a diagnosis that includes significant social communication deficits/delays along with restricted patterns of interests and behaviors. The prevalence of this diagnosis has increased over the past few decades, and it is unclear whether this is solely attributable to the increased awareness of milder forms of the disorder among medical providers. The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis. Children and adolescents with autism spectrum disorder appear to be more susceptible to adverse effects with medications; therefore, initiation with low doses and titrating very slowly is recommended. Some complementary alternative treatments have been researched as possible treatments in autism, though evidence supporting many of these is very limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Christensen, D. L., Baio, J., Braun, K. V. N., Bilder, D., Charles, J., Constantino, J. N., Daniels, J., Durkin, M. S., Fitzgerald, R. T., Kurzius-Spencer, M., et al. (2016) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6503a1 · Cited by 1,964
RetractedThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
Behavioral treatment and normal educational and intellectual functioning in young autistic children.
Lovaas, O. I. (1987) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.55.1.3 · Cited by 3,288
Dawson, G., Rogers, S., Munson, J., Smith, M., Winter, J., Greenson, J., Donaldson, A., & Varley, J. (2010) · Pediatrics · doi:10.1542/peds.2009-0958 · Cited by 2,835
Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Green, J., Charman, T., McConachie, H., Aldred, C., Slonims, V., Howlin, P., Le Couteur, A., Leadbitter, K., Hudry, K., Byford, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60587-9 · Cited by 857
Randomized Controlled Caregiver Mediated Joint Engagement Intervention for Toddlers with Autism
Kasari, C., Gulsrud, A. C., Wong, C., Kwon, S., & Locke, J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0955-5 · Cited by 751
Magiati, I., Tay, X. W., & Howlin, P. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.11.002 · Cited by 632
Research works printed but not linked: 107
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth. Arlington, VA: American Psychiatric Publishing; 2013. · DOI · Paper page
- Lai MC, Lombardo MV, Baron-Cohen S Autism. The Lancet. 2014;383:896–910. · DOI · Paper page
- Volkmar F, Siegel M, Woodbury-Smith M et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53(2):237–257. · DOI · Paper page
- Blumberg SJ, Bramlett MD, Kogan MD et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged US Children: 2007 to 2011–2012. National Health Statistics Reports. 2013;65:1–11.
- Landa R. Early communication development and intervention for children with autism. Mental Retardation and Developmental Disabilities Research Reviews. 2007;13(1):16–25. · DOI · Paper page
- Ingersoll B, Schreibman L. Teaching reciprocal imitation skills to young children with autism using a naturalistic behavioral approach: effects on language, pretend play, and joint attention. Journal of Autism and Developmental Disorders. 2006;36(4):487–505. · DOI · Paper page
- Koegel LK, Koegel RL, Harrower JK. Pivotal response intervention I: overview of approach. Research and Practice for Persons with Severe Disabilities. 1999;24(3):174–185. · DOI · Paper page
- Hardan AY, Gengoux GW, Berquist KL et al. A randomized controlled trial of pivotal response treatment group for parents of children with autism. The Journal of Child Psychology and Psychiatry. 2015;56(8):884–892. · DOI · Paper page
- Mohammadzaheri F, Koegel LK, Rezaee M, Rafiee SM. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) for children with autism. Journal of Autism and Developmental Disorders. 2014;44:2769–2777. · DOI · Paper page
- Mohammadzaheri F, Koegel LK, Rezaei M, Bakhshi E. A randomized clinical trial comparison between pivotal response treatment (PRT) and adult-driven applied behavior analysis (ABA) intervention on disruptive behaviors in public school children with autism. Journal of Autism and Developmental Disorders. 2015;45:2899–2907. · DOI
- Landa RJ, Holman KC, O’Neill AH, Stuart EA. Intervention targeting development of socially synchronous engagement in toddlers with autism spectrum disorder: a randomized controlled trial. Journal of Child Psychology and Psychiatry. 2011;52(1):13–21. · DOI · Paper page
- Oosterling I, Visser J, Swinkels S et al. Randomized controlled trial of the focus parent training for toddlers with autism: 1-year outcome. Journal of Autism and Developmental Disorders. 2010;40:1447–1458. · DOI · Paper page
- Wetherby AM, Guthrie W, Woods J et al. Parent-implemented social intervention for toddlers with autism: an RCT. Pediatrics. 2014;134(6):1084–1093. · DOI · Paper page
- Kasari C, Lawton K, Shih W et al. Caregiver-mediated intervention for low-resourced preschoolers with autism: an RCT. Pediatrics. 2014;134(1):e72–e79. · DOI · Paper page
- Otero TL, Schatz RB, Merrill AC, Bellini S. Social skills training for youth with autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America. 2015;24(1):99–115. · DOI
- White SW, Koenig K, Scahill L. Social skills development in children with autism spectrum disorders: a review of the intervention research. Journal of Autism and Developmental Disorders. 2007;37:1858–1868. · DOI · Paper page
- Whalon KJ, Conroy MA, Martinez JR, Werch BL. School-based peer-related social competence interventions for children with autism spectrum disorder: a meta-analysis and descriptive review of single case research design studies. Journal of Autism and Developmental Disorders. 2015;45:1513–1531. · DOI
- Van Steensel FJA, Bogels SM. CBT for anxiety disorders in children with and without autism spectrum disorders. Journal of Consulting and Clinical Psychology. 2015;83(3):512–523. · DOI · Paper page
- Storch EA, Lewin AB, Collier AB et al. A randomized controlled trial of cognitive-behavioral therapy versus treatment as usual for adolescents with autism spectrum disorders and comorbid anxiety. Depression and Anxiety. 2015;32(3):174–181. · DOI · Paper page
- Aman MG, Sing NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency. 1985;89:485–491. · DOI · Paper page
- Shea S, Turgay A, Carroll A et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634–e641. · DOI · Paper page
- Schopler E, Mesibov GB, Renner BR. Los Angeles, CA: Western Psychological Press; 1988. The Childhood Autism Rating Scale (CARS)
- Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry. 2005;162(7):1361–1369. · DOI · Paper page
- Troost P, Lahuis B, Steenhuis MP et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44(11):1137–1144. · DOI · Paper page
- Aman M, Rettiganti M, Nagaraja H et al. Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology. 2015;25(6):482–493. · DOI · Paper page
- Miral S, Gencer O, Inal-emiroglu FN et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. European Child and Adolescent Psychiatry. 2008;17(1):1–8. · DOI
- McDougle CJ, Scahill L, Aman MG et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psyhchopharmacology. American Journal of Psychiatry. 2005;162(2):1142–1148. · DOI · Paper page
- Freeman BJ, Ritvo ER, Yokota A, Rivo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the Academy of Child and Adolescent Psychiatry. 1986;25:130–136. · DOI
- Williams S, Scahill L, Vitiello B et al. Risperidone and adaptive behavior in children with autism. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45(4):431–439. · DOI
- Marcus R, Owen R, Kamen L et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(11):1110–1119. · DOI · Paper page
- Findling RL, Mankoski R, Timko K et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry. 2014;75(1):22–30. · DOI · Paper page
- Hollander E, Wasserman S, Swanson EN et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology. 2006;16(5):541–548. · DOI · Paper page
- Kemner C, Willemsen-Swinkels S, De Jonge M et al. Open-label study of olanzapine in children with pervasive developmental disorder. Journal of Clinical Psychopharmacology. 2002;22(5):455–460. · DOI
- Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Medical Principles and Practice. 2008;17:415–418. · DOI
- Loebel A, Brams M, Goldman RS et al. Lurasidone for the treatment of irritability associated with autistic disorder. Journal of Autism and Developmental Disorders. 2016;46:1153–1163. · DOI · Paper page
- Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology. 1999;9(2):99–107. · DOI · Paper page
- Findling RL, McNamara NK, Gracious BL et al. Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology. 2004;14(2):287–294. · DOI · Paper page
- Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clinical Neuropharmacology. 2011;34(6):216–219. · DOI
- Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. Journal of Child and Adolescent Psychopharmacology. 2007;17(6):779–790. · DOI · Paper page
- McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41(8):921–927. · DOI · Paper page
- Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology. 2012;223:237–245. · DOI
- Campbell M, Anderson LT, Small AM et al. The effects of haloperidol on learning and behavior in autistic children. Journal of Autism and Developmental Disorders. 1982;12(2):167–175. · DOI
- Anderson LT, Campbell M, Grega DM et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry. 1984;141(10):1195–1202. · DOI · Paper page
- Anderson LT, Campbell M, Adams P et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders. 1989;19(2):227–239. · DOI · Paper page
- Perry R, Campbell M, Adams P et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. Journal of the American Academy of Child and Adolescent Psychiatry. 1989;28(1):87–92. · DOI · Paper page
- Campbell M, Armenteros JL, Malone RP et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Association of Child and Adolescent Psychiatry. 1997;36(6):835–843. · DOI · Paper page
- Hollander E, Phillips A, Chaplin W et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005;30:582–589. · DOI · Paper page
- Study of Fluoxetine in Autism (SOFIA) Autism Speaks Press Release, February 18, 2009. 2016 May 6; Available online at: http://www.autismspeaks.org/about-us/press-releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia.
- Cook EH, Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry. 1992;31(4):739–745. · DOI · Paper page
- McDougle CJ, Kresch LE, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord. 2000;30:427–435. · DOI · Paper page
- Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. Journal of Autism and Developmental Disorders. 2003;33(1):77–85. · DOI
- Owley T, Walton L, Salt J et al. An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2005;44(4):343–348. · DOI
- Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. Journal of Child Neurology. 2000;15(2):132–135. · DOI · Paper page
- Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology. 2001;11(3):267–277. · DOI · Paper page
- Sanchez L, Campbell M, Small A et al. A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry. 1996;35(4):537–544. · DOI · Paper page
- Brasic JR, Barnett JY, Sheitman BB et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994;44(7):1309–1312. · DOI · Paper page
- Gordon CT, State RC, Nelson JE et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry. 1993;50:441–447. · DOI · Paper page
- Hollander E, Chaplin W, Soorya L et al. Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010;35:990–998. · DOI · Paper page
- Hollander E, Soorya L, Wasserman S et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. International Journal of Neuropsychopharmacology. 2006;9:209–213. · DOI · Paper page
- Belsito KM, Law PA, Kirk KS, Lana RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders. 2001;31(2):175–181. · DOI · Paper page
- Pearson DA, Santos CW, Aman MG et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism Spectrum disorders and AHDD symptoms. Journal of Child and Adolescent Psychopharmacology. 2013;23(5):337–351. · DOI · Paper page
- Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders. 2000;30(3):245–255. · DOI · Paper page
- Quintana H, Birmaher B, Stedge D et al. Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders. 1995;25(3):287–294. · DOI · Paper page
- Harfterkamp M, Buitelaar JK, Minderaa RB et al. Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change. Journal of Child and Adolescent Psychopharmacology. 2014;24(9):481–485. · DOI
- Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry. 1992;53(3):77–82.
- Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, van Engeland Herman. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research. 1995;58:203–215. · DOI
- Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry. 1995;34(2):223–231. · DOI
- Willemsen-Swinkels SHN, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biological Psychiatry. 1996;39:1023–1031. · DOI
- Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. Journal of the Academy of Child and Adolescent Psychiatry. 1999;38(5):587–593. · DOI
- Campbell M, Anderson LT, Small AM et al. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacology Bulletin. 1990;26(1):130–135.
- Guastella AJ, Einfeld SL, Gray KM et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry. 2010;67:692–694. · DOI · Paper page
- Chez MG, Buchanan TM, Becker M et al. Donepezil hydrochloride: a double-blind study in autistic children. Journal of Pediatric Neurology. 2003;1(2):83–88.
- Geier DA, Kern JK, Davis G et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Medical Science Monitor. 2011;17(6):PI15–PI23. · DOI · Paper page
- Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. The British Medical Journal. 201202;325:1422. · DOI · Paper page
- King BH, Wright DM, Handen BL et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2001;40(6):658–665. · DOI · Paper page
- Veenstra-Vanderweele J, Sikich L, Melmed R et al. Randomized, controlled, phase 2 trial of STX209 for social function in autism spectrum disorder. International Society of Autism Research Annual Meeting. 2013;102:001.
- Wasserman S, Iyengar R, Chaplin WF et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. International Clinical Psychopharmacology. 2006;21(6):363–367. · DOI · Paper page
- Akhondzadeh S, Fallah J, Mohammadi M et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34:32–36. · DOI
- Nikoo M, Radnia H, Rarokhnia M et al. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clinical Neuropharmacology. 2015;38(1):11–17. · DOI · Paper page
- Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of n-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13(196):1–7. · DOI · Paper page
- Ghaleiha A, Mohammadi E, Mohammadi M et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Pediatric Drugs. 2013;15:505–514. · DOI
- Ghaleiha A, Asadabadi M, Mohammadi M et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2013;16:783–789. · DOI · Paper page
- Mohammadi M, Yadegari N, Hassanzadeh E et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clinical Neuropharmacology. 2013;36(6):179–184. · DOI · Paper page
- Asadabadi M, Mohammadi M, Ghanizadeh A et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology. 2013;225:51–59. · DOI
- Ghaleiha A, Rasa SM, Nikoo M et al. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Research. 2015;229:181–187. · DOI
- Ghanizadeh A, Ayoobzadehshirazi A. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism. Pediatric Neurology. 2015;52:77–81. · DOI
- Akhondzadeh S, Erfani S, Mohammadi M et al. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 2004;29:145–150. · DOI
- Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. Journal of Sleep Research. 2012;21:700–709. · DOI · Paper page
- Wright B, Sims D, Smart S et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. Journal of Autism and Developmental Disorders. 2011;41:175–184. · DOI · Paper page
- Wirojanan J, Jacquemont S, Diaz R et al. The efficacy of melatonin for sleep problems in children with autism, fragile x syndrome, or autism and fragile x syndrome. Journal of Clinical Sleep Medicine. 2009;5(2):145–150. · DOI · Paper page
- Wasdell MB, Jan JE, Bomben MM et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. Journal of Pineal Research. 2008;44:57–64. · DOI · Paper page
- Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child: Care, Health and Development. 2006;32(5):585–589. · DOI · Paper page
- Bent S, Hendren RL, Zandi T et al. Internet-based, randomized controlled trial of omega-3 fatty acids for hyperactivity in autism. Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53(6):658–666. · DOI · Paper page
- Bertoglio K, James SJ, Deprey L et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. The Journal of Alternative and Complementary Medicine. 2010;16(5):555–560. · DOI · Paper page
- Hendren RL, James SJ, Widjaja F et al. Randomized, placebo-controlled trial of methyl B12 for children with autism. Journal of Child and Adolescent Psychopharmacology. 2006 Feb 18; [Epub ahead of print]
- Hardan AU, Fung LK, Libove RA et al. A randomized controlled pilot trial of oral n-acetylcysteine in children with autism. Biological Psychiatry. 2012;71:956–961. · DOI · Paper page
- Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. The Journal of Alternative and Complementary Medicine. 2004;10(6):1033–1039. · DOI · Paper page
- Adams JB, Audhya T, McDonough-Means S et al. Effect of a vitamin/mineral supplement on children and adults with autism. BioMed Central Pediatrics. 2011;11:1–30. · DOI · Paper page
- Munasinghe S, Oliff C, Finn J, Wray J. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. Journal of Autism and Developmental Disorders. 2010;40:1131–1138. · DOI
- Hyman SL, Stewart PA, Foley J et al. The gluten-free/casein-free diet: a double-blind challenge trial in children with autism. Journal of Autism and Developmental Disorders. 2016;46(1):205–220. · DOI · Paper page
- Gupta S. Treatment of children with autism with intravenous immunoglobulin. Journal of Child Neurology. 1999;14(3):203–205.
- DelGiudice-Asch G, Simon L, Schmeidler J et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. Journal of Autism and Developmental Disorders. 1999;29(2):157–160. · DOI
- Plioplys AV. Intravenous immunoglobulin treatment of children with autism. Journal of Child Neurology. 1998;13(2):79–82. · DOI · Paper page
- Hendren RL. Autism: biomedical complementary treatment approaches. The Child and Adolescent Psychiatric Clinics of North America. 2013;22(3):443–456. · DOI
- Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B – behavioral results. BioMed Central Pharmacology. 2009;9(17):1–9. · DOI
- Adams JB, Baral M, Geis E et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A – medical results. BioMed Central Pharmacology. 2009;9(16):1–22. · DOI · Paper page
- Brent J. Commentary on the abuse of metal chelation therapy in patients with autism spectrum disorders. Journal of Medical Toxicology. 2013;9:370–372. · DOI
Cited by
“Autism is me”: an investigation of how autistic individuals make sense of autism and stigma
Botha, M., Dibb, B., & Frost, D. M. (2022) · Disability & Society · doi:10.1080/09687599.2020.1822782 · Cited by 412
“Neither a cause, nor a cure have been found (DeFilippis and Wagner 2016).”
BackgroundRole of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation
Taniya, M. A., Chung, H.-J., Al Mamun, A., Alam, S., Aziz, M. A., Emon, N. U., Islam, M. M., Hong, S.-T. S., Podder, B. R., Ara Mimi, A., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.915701 · Cited by 207
Neural circuits regulating prosocial behaviors
Walsh, J. J., Christoffel, D. J., & Malenka, R. C. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01348-8 · Cited by 72
Shao, E., Chang, C.-W., Li, Z., Yu, X., Ho, K., Zhang, M., Wang, X., Simms, J., Lo, I., Speckart, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm5527 · Cited by 54
Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder
Markopoulos, A., Inserra, A., De Gregorio, D., & Gobbi, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749068 · Cited by 46
The Role of Cholesterol and Fatty Acids in the Etiology and Diagnosis of Autism Spectrum Disorders
Esposito, C. M., Buoli, M., Ciappolino, V., Agostoni, C., & Brambilla, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073550 · Cited by 39
“The restricted pattern of behavior also applies to the field of interests, which tends to be characterized by narrowness and repetitiveness [8].”
Background
Metadata
- Authors
- DeFilippis, M., & Wagner, K. D.
- Venue
- Psychopharmacology Bulletin
- Publisher
- MedWorks Media
- Published
- 2025-08-12
- Volume
- 46
- Issue
- 2
- Pages
- 18-41
- ISSN
- 0048-5764 (ISSN-L)
- 2472-2448
- OpenAlex
- W2540591581
- Cited by
- 177
- References
- 39
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.